Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease.
作者信息
Vuijk Stephanie A, de Ridder Lissy
机构信息
Department of Paediatric Gastroenterology, Erasmus Medical Center/Sophia Children's Hospital, Rotterdam, The Netherlands.
出版信息
Aliment Pharmacol Ther. 2023 Mar;57(5):565-566. doi: 10.1111/apt.17321.
PMID:36786458
Abstract
摘要
相似文献
1
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease.社论：改善维多珠单抗在青少年炎症性肠病患者中的药代动力学方面的成就与未解决的问题
Aliment Pharmacol Ther. 2023 Mar;57(5):565-566. doi: 10.1111/apt.17321.
2
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease-authors' reply.社论：改善炎症性肠病青少年患者维多珠单抗药代动力学的成就与未解决的问题——作者回复
Aliment Pharmacol Ther. 2023 Mar;57(5):567-568. doi: 10.1111/apt.17337.
3
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.维多珠单抗在溃疡性结肠炎和克罗恩病患者中的群体药代动力学-药效学
Aliment Pharmacol Ther. 2015 Jul;42(2):188-202. doi: 10.1111/apt.13243. Epub 2015 May 20.
4
Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases.大量炎症性肠病患者中维多珠单抗水平、抗维多珠单抗抗体与内镜愈合指数之间的关联
Dig Dis Sci. 2021 Oct;66(10):3563-3569. doi: 10.1007/s10620-020-06669-6. Epub 2020 Oct 22.
5
Editorial: vedolizumab in inflammatory bowel diseases-less is more?社论：维多珠单抗治疗炎症性肠病——少即是多？
Aliment Pharmacol Ther. 2021 Feb;53(3):443-444. doi: 10.1111/apt.16191.
6
Editorial: vedolizumab in inflammatory bowel diseases-less is more? Authors' reply.社论：维多珠单抗治疗炎症性肠病——少即是多？作者回复。
Aliment Pharmacol Ther. 2021 Feb;53(3):445-446. doi: 10.1111/apt.16227.
7
Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease.英夫利昔单抗和维得利珠单抗治疗炎症性肠病的治疗药物监测。
Inflamm Bowel Dis. 2018 Sep 15;24(10):2165-2172. doi: 10.1093/ibd/izy134.
8
Vedolizumab (Entyvio) for inflammatory bowel disease.维多珠单抗（恩特维尤）用于治疗炎症性肠病。
Med Lett Drugs Ther. 2014 Sep 15;56(1451):86-8.
9
Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease.维多珠单抗在老年炎症性肠病患者中安全有效。
Inflamm Bowel Dis. 2017 Apr;23(4):E17. doi: 10.1097/MIB.0000000000001071.
10
Efficacy of Vedolizumab for Inflammatory Bowel Disease in the Setting of DiGeorge Syndrome.维多珠单抗在迪格奥尔格综合征背景下治疗炎症性肠病的疗效。
J Pediatr Gastroenterol Nutr. 2019 May;68(5):e88. doi: 10.1097/MPG.0000000000002322.
Zotero 插件